Sinclair is pleased with its achievements for the six months ending December 31st 2008, it has asserted.
For the second half of the last financial year, total revenues for the international specialty pharmaceutical company were up 56 per cent to 16.2 million pounds.
Its gross profit also increased to 11.8 million pounds, a growth of 77 per cent.
The firm stated its sales in Europe had been strengthened with the acquisition of the minority interest in Laboratotios Novo Pharma SL in Spain, adding it had also signed 25 new distribution agreements covering 16 products in 14 markets.
Non-executive chairman of the business Grahame Cook explained that the positive half year performance demonstrated the ongoing strength of its business model and product portfolio.
He commented: "We are confident about continuing our positive progress during the second half of the year."
In other news, Sinclair singed an agreement earlier this month with BMG Pharma. The deal is thought to present it with significant pipeline development opportunities and new product assets.See all the latest jobs in Pharmaceutical